What Happened to Peptide Sciences

On March 6, 2026, Peptide Sciences — one of the largest "research peptide" vendors in the United States — displayed a shutdown notice on its website. The company, which retailer analytics firm Grips Intelligence estimated was generating approximately $7.45 million per month in revenue with roughly 37,729 monthly transactions, is no longer accepting orders.

The shutdown is part of a broader pattern of enforcement actions against gray-market peptide vendors that has accelerated since late 2024.

What happened

Peptide Sciences sold injectable peptides under "research use only" disclaimers — a legal framing that federal regulators have increasingly rejected. The FDA evaluates intended use based on the totality of evidence, not labels. When peptides are sold alongside bacteriostatic water, with dosing information, to individual consumers, the FDA treats them as unapproved drugs regardless of what the label says.

The "research use only" defense is effectively dead. The FDA has called these disclaimers a "ruse" and has pursued criminal prosecutions, warning letters, and warehouse raids against vendors using this approach.

Peptide Sciences' closure follows a series of documented enforcement actions against similar companies:

Tailor Made Compounding — DOJ criminal prosecution, $1.79M forfeiture, guilty plea
Paradigm Peptides — DOJ criminal prosecution, guilty pleas in December 2025
Amino Asylum — FDA warehouse raid in June 2025, site remains offline
50+ FDA warning letters to GLP-1 compounders in September 2025
130+ Novo Nordisk lawsuits against compounders selling semaglutide alternatives

Why it matters

The customers who relied on Peptide Sciences and similar vendors don't disappear — they need a new path. "Peptide Sciences" still generates approximately 74,000 monthly searches on Google, suggesting a large population of users actively looking for alternatives.

This demand is migrating in several directions:

Telehealth platforms like Eden, Hone Health, and BeyondMD that offer physician-prescribed peptide therapy
Compounding pharmacies that work with prescribers to fill legitimate prescriptions
Remaining gray-market vendors — though these face the same enforcement pressure
Cessation — some users stop using peptides entirely when their source disappears

The quality problem

Beyond the legal issues, gray-market peptide quality has been a persistent concern. Third-party testing data paints a troubling picture:

43% of gray-market peptides failed purity claims in Janoshik testing (2024)
23% of retatrutide samples contained the wrong molecule entirely
8% endotoxin contamination rate across tested samples

These numbers underscore why the shift toward legitimate channels — while disruptive — may ultimately benefit consumers who want to know what they're actually injecting.

What comes next

The regulatory landscape is evolving rapidly. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. signaled that approximately 14 peptides currently on the FDA's Category 2 restricted list could be moved to Category 1, which would allow licensed compounding pharmacies to compound them with a valid prescription.

As of March 16, 2026, no formal FDA action has implemented the Kennedy reclassification. The signal is promising, but it remains a political statement, not a regulatory rule change. We're tracking this in our Kennedy Reclassification Tracker.

If the reclassification proceeds, it would create a legal pathway for many of the peptides that were previously only available through gray-market vendors — including popular compounds like BPC-157. Combined with the enforcement pressure that's closing those vendors, the market appears to be shifting toward a more regulated, physician-mediated model.

What this means for you

If you were sourcing peptides from Peptide Sciences or a similar vendor:

Don't panic. The peptides you already have don't change because a vendor shut down.
Consider the quality question. Gray-market peptides have documented quality issues. A legitimate compounding pharmacy with proper quality controls may be a safer source.
Talk to a prescriber. Many peptides can be legally prescribed and compounded today. Telehealth platforms make this accessible nationwide.
Stay informed. The regulatory landscape is changing quickly. We'll continue tracking enforcement actions, reclassification developments, and access pathways.

This article reflects information available as of March 16, 2026. Regulatory status and enforcement actions are evolving. Always consult a licensed healthcare provider before starting any peptide therapy.

References

[1]
Grips Intelligence. “Peptide Sciences retailer traffic and transaction estimates.” 2026. Link
Third-party retailer analytics platform providing estimated revenue and transaction data.
[2]
Janoshik Analytical. “Public peptide testing database — 2024 aggregate results.” 2024. Link
Independent analytical testing laboratory (Prague). Widely used in the research peptide community.
[3]
U.S. Department of Justice. “Pharmacy owner pleads guilty in connection with compounding scheme.” 2024. Link
DOJ press release regarding Tailor Made Compounding prosecution and $1.79M forfeiture.
[4]
U.S. Department of Justice. “Paradigm Peptides operators plead guilty to distribution of unapproved drugs.” 2025. Link
DOJ press release regarding Paradigm Peptides criminal prosecution.
[5]
U.S. Food and Drug Administration. “Warning letters to compounding firms regarding GLP-1 receptor agonist products.” 2025. Link
FDA issued 50+ warning letters to GLP-1 compounders in September 2025.